FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113138439> ?p ?o ?g. }

• W2113138439 endingPage "2524" @default.
• W2113138439 startingPage "2524" @default.
• W2113138439 abstract "One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement. Recently, Hoffman-LaRoche Pharmaceuticals, following reports of 20 deaths from ticlopidine-associated TTP, updated the information about the hematologic adverse effects of the drug.To review our recent findings on ticlopidine-associated hematologic toxic effects, which served as the impetus for the revised warnings, and to discuss the implications of these findings.Data were obtained from the Food and Drug Administration's MedWatch program, published phase 3 clinical trials and case reports, hematologists, and plasmapheresis centers.No cases of TTP have been reported in phase 3 ticlopidine trials. In contrast, postmarketing surveillance has identified serious adverse drug reactions to ticlopidine, resulting in 259 deaths, with TTP accounting for 40 of these deaths. Detailed information was available on 98 cases of ticlopidine-associated TTP. Compared with 42 patients in the coronary artery stent setting, 56 patients with ticlopidine-associated TTP in the stroke prevention setting were more likely to be women (62.5% vs 28.6%; P = .01). Before the onset of TTP in patients receiving stroke prevention therapy and patients with stent placement, ticlopidine had been used for less than 2 weeks in 5.4% and 2.4%, between 2 and 3 weeks in 17.9% and 21.4%, between 3 and 4 weeks in 30.4% and 38.1%, and between 4 and 12 weeks in 46.4% and 38.1%, respectively. Death occurred in almost 60% of all patients not receiving plasmapheresis compared with 21.9% of patients receiving plasmapheresis for stroke prevention and 14.3% of patients receiving plasmapheresis in the stent setting.Use of ticlopidine requires frequent physician visits and laboratory tests for at least 3 months in the stroke prevention setting, while, with short-term use in the coronary artery stent setting, adverse events are less likely to occur. These factors, as well as competition from clopidogrel bisulfate, a new antiplatelet agent, potentially limit the feasibility of ticlopidine as a stroke prevention agent, while having less impact on its use following coronary artery stent placement." @default.
• W2113138439 created "2016-06-24" @default.
• W2113138439 creator A5021357839 @default.
• W2113138439 creator A5037456539 @default.
• W2113138439 creator A5052469404 @default.
• W2113138439 creator A5064356834 @default.
• W2113138439 creator A5076933022 @default.
• W2113138439 creator A5089700881 @default.
• W2113138439 date "1999-11-22" @default.
• W2113138439 modified "2023-10-03" @default.
• W2113138439 title "Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine in the Setting of Coronary Artery Stents and Stroke Prevention" @default.
• W2113138439 cites W1966779915 @default.
• W2113138439 cites W2021374170 @default.
• W2113138439 cites W2033006997 @default.
• W2113138439 cites W2043540236 @default.
• W2113138439 cites W2043896622 @default.
• W2113138439 cites W2045319650 @default.
• W2113138439 cites W2080649274 @default.
• W2113138439 cites W2083065622 @default.
• W2113138439 cites W2148132508 @default.
• W2113138439 cites W2315229770 @default.
• W2113138439 cites W2318352361 @default.
• W2113138439 cites W2327850977 @default.
• W2113138439 cites W2329490408 @default.
• W2113138439 cites W2340760838 @default.
• W2113138439 cites W2412800815 @default.
• W2113138439 cites W311320695 @default.
• W2113138439 cites W3151407768 @default.
• W2113138439 cites W2516284903 @default.
• W2113138439 cites W3147102246 @default.
• W2113138439 doi "https://doi.org/10.1001/archinte.159.21.2524" @default.
• W2113138439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10573042" @default.
• W2113138439 hasPublicationYear "1999" @default.
• W2113138439 type Work @default.
• W2113138439 sameAs 2113138439 @default.
• W2113138439 citedByCount "124" @default.
• W2113138439 countsByYear W21131384392012 @default.
• W2113138439 countsByYear W21131384392013 @default.
• W2113138439 countsByYear W21131384392014 @default.
• W2113138439 countsByYear W21131384392015 @default.
• W2113138439 countsByYear W21131384392016 @default.
• W2113138439 countsByYear W21131384392017 @default.
• W2113138439 countsByYear W21131384392018 @default.
• W2113138439 countsByYear W21131384392019 @default.
• W2113138439 countsByYear W21131384392021 @default.
• W2113138439 crossrefType "journal-article" @default.
• W2113138439 hasAuthorship W2113138439A5021357839 @default.
• W2113138439 hasAuthorship W2113138439A5037456539 @default.
• W2113138439 hasAuthorship W2113138439A5052469404 @default.
• W2113138439 hasAuthorship W2113138439A5064356834 @default.
• W2113138439 hasAuthorship W2113138439A5076933022 @default.
• W2113138439 hasAuthorship W2113138439A5089700881 @default.
• W2113138439 hasBestOaLocation W21131384391 @default.
• W2113138439 hasConcept C126322002 @default.
• W2113138439 hasConcept C127413603 @default.
• W2113138439 hasConcept C141071460 @default.
• W2113138439 hasConcept C187212893 @default.
• W2113138439 hasConcept C197636746 @default.
• W2113138439 hasConcept C197934379 @default.
• W2113138439 hasConcept C2777265216 @default.
• W2113138439 hasConcept C2777849778 @default.
• W2113138439 hasConcept C2778213512 @default.
• W2113138439 hasConcept C2778583881 @default.
• W2113138439 hasConcept C2778585876 @default.
• W2113138439 hasConcept C2778905298 @default.
• W2113138439 hasConcept C2780645631 @default.
• W2113138439 hasConcept C500558357 @default.
• W2113138439 hasConcept C71924100 @default.
• W2113138439 hasConcept C78519656 @default.
• W2113138439 hasConcept C89560881 @default.
• W2113138439 hasConceptScore W2113138439C126322002 @default.
• W2113138439 hasConceptScore W2113138439C127413603 @default.
• W2113138439 hasConceptScore W2113138439C141071460 @default.
• W2113138439 hasConceptScore W2113138439C187212893 @default.
• W2113138439 hasConceptScore W2113138439C197636746 @default.
• W2113138439 hasConceptScore W2113138439C197934379 @default.
• W2113138439 hasConceptScore W2113138439C2777265216 @default.
• W2113138439 hasConceptScore W2113138439C2777849778 @default.
• W2113138439 hasConceptScore W2113138439C2778213512 @default.
• W2113138439 hasConceptScore W2113138439C2778583881 @default.
• W2113138439 hasConceptScore W2113138439C2778585876 @default.
• W2113138439 hasConceptScore W2113138439C2778905298 @default.
• W2113138439 hasConceptScore W2113138439C2780645631 @default.
• W2113138439 hasConceptScore W2113138439C500558357 @default.
• W2113138439 hasConceptScore W2113138439C71924100 @default.
• W2113138439 hasConceptScore W2113138439C78519656 @default.
• W2113138439 hasConceptScore W2113138439C89560881 @default.
• W2113138439 hasIssue "21" @default.
• W2113138439 hasLocation W21131384391 @default.
• W2113138439 hasLocation W21131384392 @default.
• W2113138439 hasOpenAccess W2113138439 @default.
• W2113138439 hasPrimaryLocation W21131384391 @default.
• W2113138439 hasRelatedWork W1530308945 @default.
• W2113138439 hasRelatedWork W1968840616 @default.
• W2113138439 hasRelatedWork W2108116405 @default.
• W2113138439 hasRelatedWork W2238271918 @default.
• W2113138439 hasRelatedWork W2317139162 @default.
• W2113138439 hasRelatedWork W2337491227 @default.

• next